Skip to main content
Clinical Trials/NL-OMON24362
NL-OMON24362
Not yet recruiting
Not Applicable

Single-cell analysis of somatic mutations to understand and improve hematopoiesis after transplantation

Princess Máxima Center for Pediatric Oncology0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Allogeneic hematopoietic stem cell transplantation
Sponsor
Princess Máxima Center for Pediatric Oncology
Enrollment
20
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Princess Máxima Center for Pediatric Oncology

Eligibility Criteria

Inclusion Criteria

  • (1\) Allogeneic HSCT with bone marrow cells from a healthy sibling donor; (2\) Age at HSCT \<18 yrs; (3\) First HSCT; (4\) Availability of viably frozen donor bone marrow cells from the Biobank of the UMC Utrecht; (5\) \>95% donor chimerism; (6\) No major HSCT\-related complications (see exclusion criteria).

Exclusion Criteria

  • (1\) Major HSCT\-related complications, such as \>grade 2 graft versus host disease; (2\) Secondary graft failure; (3\) Objection to be notified about actionable findings from whole\-genome sequencing; (4\) Failure of the HSCT recipient, donor and/or their legal representatives to understand the patient information and informed consent form (either due to intellectual disability or to language problems). Of note: Only include subjects in whom both the HSCT recipient and his/her donor (and, if applicable, their caregivers) agree to participate in the current study are eligible.

Outcomes

Primary Outcomes

Not specified

Similar Trials